Aurinia Pharmaceuticals Inc(AUPH)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

AUPH Aurinia Pharmaceuticals Inc

交易中 10-13 12:08:16 EDT

16.45

-0.10

-0.60%

最高16.58	最低16.32	成交量25.04万
今开16.46	昨收16.55	日振幅1.57%
总市值21.89亿	流通市值21.22亿	总股本1.33亿
成交额412.00万	换手率0.19%	流通股本1.29亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"AUPH","market":"US","secType":"STK","nameCN":"Aurinia Pharmaceuticals Inc","latestPrice":16.45,"timestamp":1791907693356,"preClose":16.55,"halted":0,"volume":250429,"delay":0,"changeRate":-0.006042296072507639,"floatShares":129000000,"shares":133051168,"eps":2.303212,"marketStatus":"交易中","change":-0.1,"latestTime":"10-13 12:08:16 EDT","open":16.46,"high":16.58,"low":16.32,"amount":4120042.6318309996,"amplitude":0.01571,"askPrice":16.46,"askSize":133,"bidPrice":16.44,"bidSize":100,"shortable":3,"etf":0,"ttmEps":2.303212,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1791921600000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":951454800000,"exchange":"NASDAQ","adjPreClose":16.55,"preHourTrading":{"tag":"盘前","latestPrice":16.45,"preClose":16.55,"latestTime":"09:28 EDT","volume":798,"amount":13269.771228000001,"timestamp":1791898093102,"change":-0.1,"changeRate":-0.006042,"amplitude":0.021148},"postHourTrading":{"tag":"盘后","latestPrice":16.54,"preClose":16.55,"latestTime":"19:30 EDT","volume":77435,"amount":1281615.9744,"timestamp":1791847802414,"change":-0.01,"changeRate":-0.000604,"amplitude":0.000604},"volumeRatio":0.8263,"impliedVol":0.4565,"impliedVolPercentile":0.498},"requestUrl":"/m/hq/s/AUPH/tweets","defaultTab":"tweets","newsList":[{"id":"1107442829","title":"Aurinia Pharmaceuticals持续推进新泽西州专利诉讼，针对多家仿制药企业","url":"https://stock-news.laohu8.com/highlight/detail?id=1107442829","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1107442829?lang=zh_cn&edition=full","pubTime":"2026-08-20 04:07","pubTimestamp":1787170073,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals Inc.（AUPH）正在新泽西州继续推进其专利诉讼，目标直指多家仿制药公司。这一法律行动凸显了该公司对其核心产品知识产权的坚定维护立场。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AUPH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196077145","title":"Aurinia制药公司：梯瓦最早或于2036年12月7日在美国推出沃克洛孢素仿制药","url":"https://stock-news.laohu8.com/highlight/detail?id=1196077145","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1196077145?lang=zh_cn&edition=full","pubTime":"2026-08-20 04:06","pubTimestamp":1787169972,"startTime":"0","endTime":"0","summary":"Aurinia制药公司近日披露，梯瓦制药可能最早要到2036年12月7日才能在美国市场推出沃克洛孢素的仿制药版本。这一时间节点的设定，为Aurinia的核心产品提供了长期的市场独占保护。沃克洛孢素作为该公司研发的关键药物，其在美专利保护期得到进一步明确。对投资者而言，这意味着未来十余年内，Aurinia在美国市场面临的仿制药竞争压力将相对有限。Aurinia Pharmaceuticals Inc是一家专注于自身免疫性疾病治疗的生物制药企业。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AUPH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162622081","title":"Aurinia Pharmaceuticals第二季度税前利润达4878.6万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1162622081","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1162622081?lang=zh_cn&edition=full","pubTime":"2026-08-06 20:19","pubTimestamp":1786018786,"startTime":"0","endTime":"0","summary":"8月6日，Aurinia Pharmaceuticals（股票代码：AUPH）公布了其第二季度财报。数据显示，公司第二季度产品收入为7941.2万美元。与此同时，该公司在报告期内实现税前利润4878.6万美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AUPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162218198","title":"Lupkynis显著降低肾脏相关事件或死亡风险达53%","url":"https://stock-news.laohu8.com/highlight/detail?id=1162218198","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1162218198?lang=zh_cn&edition=full","pubTime":"2026-06-04 19:02","pubTimestamp":1780570951,"startTime":"0","endTime":"0","summary":"研究数据显示，药物Lupkynis与肾脏相关事件或死亡风险出现统计学上显著降低53%相关。这一发现突显了该疗法在改善患者临床结局方面的潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AUPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141334772","title":"Aurinia Pharmaceuticals公布2026年第一季度财报及近期业务进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1141334772","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1141334772?lang=zh_cn&edition=full","pubTime":"2026-05-07 20:01","pubTimestamp":1778155297,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals Inc（以下简称“Aurinia”）近日披露了截至2026年3月31日的第一季度财务业绩，并同步更新了公司近期的业务动态。\n财报数据显示，本季度Aurinia在核心产品市场推广及研发管线推进方面取得显著进展。公司管理层表示，当前财务表现符合预期，各项运营指标保持稳健态势。\n与此同时，Aurinia还重点介绍了其在自身免疫疾病领域的最新研究突破。通过持续优化临床治疗方案，公司正加速拓展全球市场布局，为长期增长注入新动能。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AUPH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163649301","title":"Aurinia Pharmaceuticals 2024年第四季度GAAP每股收益$0.01超出$(0.02)的预期，销售额$59.87M低于$59.94M的预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1163649301","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1163649301?lang=zh_cn&edition=full","pubTime":"2025-02-27 19:05","pubTimestamp":1740654320,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals  报告称季度每股收益为$0.01，超过了分析师一致预期的$，超出150%。公司报告的季度销售额为$59.87百万，低于分析师一致预期的$59.94百万，差距为0.13%。与去年同期$45.09百万的销售额相比，这增加了32.76%。以上内容来自Benzinga Earnings专栏，原文如下：Aurinia Pharmaceuticals  reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $ by 150 percent. This is a 105.26 percent increase over losses of $ per share from the same period last year.  The company reported quarterly sales of $59.87 million which missed the analyst consensus estimate o","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Aurinia Pharmaceuticals 2024年第四季度GAAP每股收益$0.01超出$(0.02)的预期，销售额$59.87M低于$59.94M的预期","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AUPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2490115780","title":"Aurinia Pharmaceuticals Inc盘中异动 大幅拉升5.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2490115780","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2490115780?lang=zh_cn&edition=full","pubTime":"2024-12-10 22:32","pubTimestamp":1733841172,"startTime":"0","endTime":"0","summary":"北京时间2024年12月10日22时32分，Aurinia Pharmaceuticals Inc股票出现波动，股价大幅上涨5.59%。截至发稿，该股报9.64美元/股，成交量19.1063万股，换手率0.13%，振幅1.53%。Aurinia Pharmaceuticals Inc股票所在的生物技术行业中，整体涨幅为0.01%。其相关个股中，Chimerix, Inc.、Uniqure N.V.、Klotho Neurosciences Inc C/Wts 21/06/2029 涨幅较大，Psyence Biomedical Ltd.、Processa Pharmaceuticals, Inc.、60 Degrees Pharmaceuticals, Inc.较为活跃，换手率分别为1717.09%、404.62%、88.15%，振幅较大的相关个股有Reviva Pharmaceuticals Holdings Inc C/Wts 25/12/2025、Psyence Biomedical Ltd.、Chimerix, Inc.，振幅分别为24.58%、21.74%、17.33%。Aurinia Pharmaceuticals Inc公司简介：Aurinia Pharmaceuticals Inc是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241210223253984b0be2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241210223253984b0be2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AUPH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2484924548","title":"Aurinia Pharmaceuticals Inc2024财年第三财季实现净利润14.35百万美元，同比增加206.69%","url":"https://stock-news.laohu8.com/highlight/detail?id=2484924548","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2484924548?lang=zh_cn&edition=full","pubTime":"2024-11-17 00:02","pubTimestamp":1731772946,"startTime":"0","endTime":"0","summary":"11月17日，Aurinia Pharmaceuticals Inc公布财报，公告显示公司2024财年第三财季净利润为14.35百万美元，同比增加206.69%；其中营业收入为67.77百万美元，同比增加24.30%，每股基本收益为0.10美元。机构评级：截至2024年11月17日，当前有7家机构对Aurinia Pharmaceuticals Inc目标价做出预测，其中目标均价为10.84美元，其中最低目标价为8.00美元，最高目标价为13.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241117000320a23e064a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241117000320a23e064a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AUPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154738439","title":"异动解读 | Aurinia Pharmaceuticals大幅裁员重组 盘中股价大涨7%","url":"https://stock-news.laohu8.com/highlight/detail?id=1154738439","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154738439?lang=zh_cn&edition=full","pubTime":"2024-11-07 22:49","pubTimestamp":1730990947,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals Inc今日盘中大涨7.06%,引发了市场的广泛关注。公司宣布将进行大规模重组,包括裁员约28%的全职员工,优化临床开发项目组合,以及外包部分非核心职能等措施。重组过程中,Aurinia将继续专注于其主打产品Lupkynis的市场推广工作,并寻求与潜在战略合作伙伴的合作,以加速实现公司的商业目标。投资者对这一重组计划反映了积极态度,公司股价盘中大涨反映了市场对其未来发展前景的充满信心。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["AUPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2481186028","title":"Aurinia Pharmaceuticals Inc盘中异动 早盘股价大涨7.05%报8.05美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2481186028","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2481186028?lang=zh_cn&edition=full","pubTime":"2024-11-07 22:31","pubTimestamp":1730989875,"startTime":"0","endTime":"0","summary":"北京时间2024年11月07日22时31分，Aurinia Pharmaceuticals Inc股票出现波动，股价大幅拉升7.05%。截至发稿，该股报8.05美元/股，成交量10.3461万股，换手率0.07%，振幅0.00%。Aurinia Pharmaceuticals Inc股票所在的生物技术行业中，整体涨幅为0.06%。其相关个股中，Tevogen Bio Holdings Inc C/Wts 14/02/2029 、Ensysce Biosciences, Inc.、Mustang Bio, Inc.涨幅较大，Ensysce Biosciences, Inc.、Elevai Labs, Inc.、Cyclacel Pharmaceuticals, Inc.较为活跃，换手率分别为76.92%、54.48%、47.54%，振幅较大的相关个股有Tuhura Biosciences, Inc.、Immunic, Inc.、Fennec Pharmaceuticals Inc.，振幅分别为8.54%、5.93%、4.85%。Aurinia Pharmaceuticals Inc公司简介：Aurinia Pharmaceuticals Inc是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241107223115a220ec2e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241107223115a220ec2e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AUPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163681819","title":"异动解读 | Aurinia Pharmaceuticals公司宣布重组计划 盘前股价大涨","url":"https://stock-news.laohu8.com/highlight/detail?id=1163681819","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1163681819?lang=zh_cn&edition=full","pubTime":"2024-11-07 22:26","pubTimestamp":1730989593,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals Inc (股票代码:AUPH)今日盘前大涨6.65%,引发市场广泛关注。公司宣布将进行重组,包括裁员和优化运营,旨在降低运营成本、提高效率。\n\nAurinia表示,在当前经济环境下,为了确保公司长期可持续发展,必须采取一些艰难但关键的措施。此次重组计划预计可节省大约1.25亿美元的年度运营支出。\n\n重组的具体内容包括裁员约28%的全职员工,优化临床开发项目组合,外包部分非核心职能等。Aurinia还将继续专注于其主打产品Lupkynis的市场推广,并寻求战略性合作伙伴关系,以加速实现商业目标。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["AUPH"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.auriniapharma.com","stockEarnings":[{"period":"1week","weight":0.0528},{"period":"1month","weight":0.028},{"period":"3month","weight":0.0357},{"period":"6month","weight":0.0312},{"period":"1year","weight":0.4685},{"period":"ytd","weight":0.0376}],"compareEarnings":[{"period":"1week","weight":0.0042},{"period":"1month","weight":0.0181},{"period":"3month","weight":0.0349},{"period":"6month","weight":0.1117},{"period":"1year","weight":0.1915},{"period":"ytd","weight":0.141}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Aurinia Pharmaceuticals Inc.是根据《商业公司法》组建的（加拿大阿尔伯塔省）。Aurinia制药是一家完全整合的生物制药公司，专注于提供治疗目标患者群体的疗法，这些患者群体受到自身免疫、肾脏和罕见病的影响，医疗需求未得到满足。2021年1月，Aurinia制药推出了首个获得FDA批准的口服药物LUPKYNIS（voclosporin），用于治疗活动性LN成人患者。LUPKYNIS是一种口服CNI免疫抑制剂，当与霉酚酸酯（MMF）（尽管MMF目前尚未被批准）和类固醇联合使用时，已被证明可以改善LN的近期和长期结果。通过抑制钙调神经磷酸酶，LUPKYNIS降低细胞因子活化，阻断白细胞介素IL-2表达和T细胞介导的免疫反应。LUPKYNIS还可能稳定足细胞，从而防止蛋白尿。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":0.071692},{"month":2,"riseRate":0.416667,"avgChangeRate":0.005745},{"month":3,"riseRate":0.5,"avgChangeRate":0.089864},{"month":4,"riseRate":0.666667,"avgChangeRate":-0.004824},{"month":5,"riseRate":0.5,"avgChangeRate":-0.007754},{"month":6,"riseRate":0.5,"avgChangeRate":-0.009565},{"month":7,"riseRate":0.583333,"avgChangeRate":0.027825},{"month":8,"riseRate":0.583333,"avgChangeRate":-0.006441},{"month":9,"riseRate":0.5,"avgChangeRate":0.058955},{"month":10,"riseRate":0.615385,"avgChangeRate":0.046883},{"month":11,"riseRate":0.583333,"avgChangeRate":0.036405},{"month":12,"riseRate":0.416667,"avgChangeRate":0.092842}],"exchange":"NASDAQ","name":"Aurinia Pharmaceuticals Inc","nameEN":"Aurinia Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Aurinia Pharmaceuticals Inc(AUPH)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Aurinia Pharmaceuticals Inc(AUPH)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Aurinia Pharmaceuticals Inc,AUPH,Aurinia Pharmaceuticals Inc股票,Aurinia Pharmaceuticals Inc股票老虎,Aurinia Pharmaceuticals Inc股票老虎国际,Aurinia Pharmaceuticals Inc行情,Aurinia Pharmaceuticals Inc股票行情,Aurinia Pharmaceuticals Inc股价,Aurinia Pharmaceuticals Inc股市,Aurinia Pharmaceuticals Inc股票价格,Aurinia Pharmaceuticals Inc股票交易,Aurinia Pharmaceuticals Inc股票购买,Aurinia Pharmaceuticals Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Aurinia Pharmaceuticals Inc(AUPH)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Aurinia Pharmaceuticals Inc(AUPH)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}